LEVOTHYROXINE MANUFACTURERS HAVE THREE YEARS TO OBTAIN NDA APPROVAL UNDER FDA POLICY; AGENCY CITES POTENCY AND STABILITY PROBLEMS WITH THYROID PRODUCTS

FDA is giving manufacturers of levothyroxine sodium three years to obtain NDA approval for their products under a new drug policy announced Aug. 14.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet